ROBERT E. MOFFIT, Ph.D.:
Welcome to the second in a series of
lectures on the governance issues in the Medicare program, the huge
federal health benefits program that covers approximately 40
million of America's senior and disabled citizens.
Medicare reform is more than simply
throwing more money at the ailing Medicare program. Real Medicare
reform would improve the range and quality of services to senior
citizens, introduce flexibility and innovation in the delivery of
medical benefits, and respect the professional integrity and
independent judgment of physicians. It is about time, then, that
policymakers in Washington look at the way in which today's
Medicare program really operates and think about ways in which a
new system could avoid the problems that beset the old one.
Congress has engaged in a major debate on
the Patients' Bill of Rights and has focused on the treatment of
doctors and patients in private-sector managed care programs. A key
issue has been managed care companies' denial of medical claims on
the grounds that insurance officials, not doctors, decided that
certain treatments or procedures were not medically necessary.
Conspicuously absent from that public discussion is the question of
the patient's rights and the right to medical care within Medicare,
the program over which Congress has direct jurisdiction.
The
Secretary of the Department of Health and Human Services (HHS) is
legally authorized to make determinations about what is a
"reasonable" and "necessary" medical service. In January of 1989,
the Health Care Financing Administration (HCFA) proposed a final
rule defining what is medically necessary or reasonable treatment,
but the rule was never finalized.
Today, the Medicare bureaucracy and its
contractors often make such determinations and deny payment for
medical services for Medicare patients, even if the services are in
many cases formally "covered" by Medicare but don't meet specific
terms and the conditions that either HCFA or their contractors say
would make those services necessary or appropriate. A lot of
Medicare claims are denied each year. Based on 1997 data supplied
by HCFA to The Heritage Foundation, 19 percent of the total
Medicare Part B claims that were denied were denied on the basis of
"medical necessity."
Moreover, doctors and patients who
challenge Medicare denials of their claims face an arduous and
time-consuming appeals process, including adjudication in
administrative law courts. In 1999, HCFA admitted that for Medicare
Part B claims alone, which are claims for physicians' services, the
average time for administrative law judges to render a decision was
524 days.
In
terms of the normal functioning of the Medicare program, this
authority is perhaps the most powerful administrative weapon in
HCFA's already vast regulatory arsenal. Timothy Blanchard wrote a
seminal article on this issue in 1990 in the St. Louis Law Review.
He said, "The process of Medicare decision making about Medicare
coverage and in particular medical necessity determinations has
been shrouded in mystery since the inception of the Medicare
Program."
"Indeed," adds counselor Blanchard, "it is
one of the most expansive bodies of secret law ever developed
against a broad segment of the American population." Mr. Blanchard
is the first of three outstanding panelists who are going to talk
about this rather arcane, but vitally important, subject.
Robert
E. Moffit, Ph.D. is the Director of Domestic Policy
Studies at The Heritage Foundation.
MEDICARE CLAIMS DENIALS BASED ON "MEDICAL
NECESSITY"
TIMOTHY BLANCHARD:
The
issues related to coverage of items and services under the Medicare
program and the processing of claims for those services have proven
to be an extremely difficult area of policymaking, both objectively
and politically. Medicare does not pay for items or services that
are not reasonable and necessary for the diagnosis of injury or
illness, or to improve the functioning of a malformed body member.
That is what the statute says.
Delegating Tough Decisions
Congress, finding this very difficult to grapple with at the
inception of the Medicare program, delegated those detailed
decisions to what is now the Department of Health and Human
Services and to the Health Care Financing Administration.
Members of Congress subsequently realized
that in processing individual claims, there would be situations in
which services were furnished that were later determined not to
have been reasonable and necessary, but that the doctor and the
patient may not, or should not, be responsible for those errors in
all cases. Consequently, Congress provided that the Medicare
program will make payment for services, even if they are
subsequently determined not to have been reasonable and necessary,
if neither the physician nor the patient knew, or should have
known, when the services were provided that they wouldn't be
considered reasonable and necessary.
This
concept is sometimes called limitation of liability; other times,
it is called waiver of liability. It sounds fair: If you didn't
know, or shouldn't have had reason to know, that a medical service
wasn't going to be considered covered, then you shouldn't be
responsible for it. In essence, that rule, on its face, would
appear to put the risk of unclear or absent regulation on the
agency responsible for making the rules: the Health Care Financing
Administration.
Of
course, the responsibility for not having made those rules falls on
the Medicare Trust Funds and, ultimately, the taxpayers. In
practice, however, the concept is turned on its head. For example,
there is a regulatory presumption that the doctor knows in every
case what is going to be reasonable and necessary. This simply is
not borne out in fact.
Double Standard
In addition, there is a double standard at work. When a doctor
prevails on appeal, that is not considered in the context of what
they know, or should know. But any denial is considered notice that
similar claims would be not considered reasonable and necessary,
even if those claims are currently on appeal and even in the event
that those appeals are ultimately favorable to the doctor or the
provider.
Finally, in areas affecting the
application of this rule, there has been a long history of refusing
to disclose the standards that would be applied in claims
processing. By that I mean, how many services? How often can they
be provided? When? Under what circumstances? The details of what is
going to be considered "reasonable" and "necessary" in the
processing of actual claims are important here. Not many of us
would disagree that it does not make sense to pay for services
through the Medicare program that are not reasonable and necessary.
The difficulty is figuring out what that really means in
practice.
In
that regard, many people believe that the Medicare program is
governed by regulation. Mostly, that is not true in
connection with medical necessity determinations and policy
development. Let me give you a quick review of the relatively long
history of this from a regulatory perspective.
-
In 1987, to settle a lawsuit, the Health
Care Financing Administration published a notice regarding the
process for medical necessity determinations.
-
In 1989, there were proposed regulations.
Years passed without any action on those rules.
-
In 1995, a final rule was published with
regard to certain investigational medical devices, but not with
regard to the vast range of other items or medical services
furnished under the program. More time passes.
-
Last year, on April 27, 1999, HCFA
published a notice in the Federal Register--not a regulation
but a "notice"-- explaining how it will make what are known as
"national coverage" decisions with regard to items or services
under the program.
The
good news here is that this particular "notice" does set out the
process HCFA intends to use. It does create an opportunity for
providers to request national coverage determinations to clarify
rules that aren't there, and does give us some criteria. The bad
news is that national coverage determinations address only a small
fraction of the items or services furnished under the Medicare
program, or that may be covered under the Medicare program.
Consequently, many services continue to be adjudicated under what
are known as Local Medical Review Policies (LMRPs) or only as ad
hoc claims processing determinations by individual carriers and
fiscal intermediaries across the country which contract with
HCFA.
In
practice, this means an identical medical service furnished in a
clinically equivalent circumstance may be covered in one part of
the country, not covered in another part of the country, and
covered in yet another part of the country only if certain
circumstances are met somewhere else. In fact, whether Medicare
will pay for, or consider covered, the same medical service for a
patient may depend on which side of the road, or which side of the
river, that patient lives; or which side of the road, or which side
of the river, and in which carrier jurisdiction the services are
provided.
Consider this analogy: If HCFA were
responsible for interstate highways, we would have a national speed
limit that went something like "reasonable and necessary; fast
enough but not too fast," with authority delegated to each state to
figure out what that meant, what's fast enough but not too fast, in
interpreting that broad policy.
This
has led to a situation where there are a lot of unmarked speed
traps, jurisdiction by jurisdiction, for doctors trying to figure
out what's going to be considered reasonable and necessary. And
this is, after all, a federal program.
There have been some developments, some
favorable and some unfavorable, in recent years. First, in
fairness, HCFA contractors have begun to implement HCFA
instructions to make the local medical review policymaking process
more open and to publish, to a greater extent than they have
historically, what those local review policies are.
Secret Standards
But we still have many secret standards in claims processing.
These are sometimes called parameters--sometimes they go by other
terms--which the agency uses to try and distinguish what it's going
to tell providers and what it won't. But they are used in claims
processing and have an impact on whether something will be
considered "covered" or "not covered."
Second, the stakes are much higher today
than they have been at any other point in the Medicare program. We
are not just talking about overpayments. We're talking about
potential exposure to civil money penalties and the application of
the False Claims Act, with its treble damages and five to ten
thousand dollar mandatory civil penalties in the event doctors are
found to submit claims that are not "medically necessary."
Third, there's no viable way to appeal
these standards without first violating them. In order to appeal
these determinations, it is essential to submit a claim and have it
denied. Then you submit yourself to a very long and arduous appeal
process which, fortunately in many cases, ends with a reversal in
favor of doctors or providers, but only after they have run the
"Medicare Appeals Pentathlon": five mandatory steps that they have
to go through in order to ultimately get to a court.
While two United States Courts of Appeals
recently interpreted the statute in a rational manner that would
have allowed a certain review to proceed prior to going through
that claims process--in other words, to figure out in advance
whether policy positions taken by the Secretary of HHS were
arbitrary and capricious or were appropriate--the United States
Supreme Court on February 29 issued a 5-4 decision that essentially
closed this avenue of review.
Thus, in order to challenge what may be
arbitrary and capricious policies with respect to which services
will be covered and which won't, a doctor has to furnish the
service, submit the claim, and put himself at risk of not only
claims denials, but also false claims exposure and potential
exclusion from the Medicare program. So let's update our highway
analogy briefly. We still have many unmarked speed traps. We have
more posted local speed zones that you can't challenge without
violating the rules first.
Just
to give you an example: Suppose a local Medicare carrier concludes
that six treatments per year is reasonable and necessary but the
physician believes that seven or eight are necessary for a
particular patient. His options are very limited. He can submit the
claim for the seventh and eighth service and then appeal through
this long process.
What's the problem with that? Well,
there's the time value of money. There's also the loss of
confidence that the patient may have in the physician, because a
patient is notified when these services are denied. He gets a
notice that says, "Medicare doesn't consider these services
reasonable and necessary." And that's not the best thing for the
doctor-patient relationship.
The
situation is actually worse than that. Many physicians specialize
and see a lot of the same kind of patients. If a physician sees a
number of patients who need that seventh, eighth, or ninth service,
he pretty quickly winds up in a situation where he could be
construed as having a pattern of furnishing unnecessary services.
And this pattern could develop before completing the appeal process
with regard to those other services. Physicians, in putting care of
their patient first, are going to proceed in that manner and try
and proceed that way as best they can.
What
other options does a physician have in this situation? If you
recall those waiver of liability concepts I mentioned, one thing
that the statute would allow them to do is give the patient notice
that Medicare is likely to deny these services based on medical
necessity grounds. If the physician does that, then the patient has
to make a decision: Am I going to pay for this myself, knowing
Medicare is not going to pay for it?
Many
times, the patient will either be unable to pay for that service or
unwilling to accept that risk, and in essence self-disallow that
medical service. The problem with that is that there hasn't been a
formal determination yet whether that service is reasonable and
necessary or not. The appeal right that the patient has in that
case still exists, but realistically it is foreclosed.
So
this is what we've got: Proceed with the appeal process, get a
denied claim, and see what happens. We've also got here a way to
shift the risk to the patient under these waiver liability
provisions and let the patient make that choice and see what
happens. I didn't mention what happens if the carrier actually pays
the claim anyway. There's a local review policy that says, "We
won't," but the claim gets paid anyway. This happens all the
time.
In
this situation, the physician may reasonably reach a conclusion
that the "published policy" is not really what it is, because I
submitted the claims for the seventh and eighth service and they
got paid. That may lead to a "pattern" of practice that seems
reasonable to the physician, but it exposes them later to challenge
on audit; someone pulls out the written policy and says, "Gosh, you
knew or should have known that the seventh and eighth weren't going
to be covered, so we're going to challenge those now."
Catch-22
The most insidious potential outcome here is that the physician
may simply decline to furnish those "on-the-margin" questionable
services to the patient, a de facto type of denial. This, of
course, exposes the physician to the challenge of furnishing
substandard care, or unprofessional conduct, and can also expose
the physician to exclusion from the program and to civil penalties.
I believe this Catch-22 is simply unconscionable, but it is there,
and it has to be dealt with on a daily basis by practitioners
trying to figure out how to work.
The
situation actually can be worse for some non-physician providers,
because they are not really in a position to say, "Well, based on
the local medical review policy, Medicare doesn't believe that the
service your physician just ordered, and which in some cases may be
quite painful to you and inconvenient, is necessary." That
certainly also is not good for the physician-patient relationship.
It undermines the beneficiary's confidence in his or her physician.
It also undermines patients' confidence in the Medicare program;
they believed it was going to cover these services.
Let
me wrap up with an analogy. It encapsulates the problem fairly
well. When I was a youth and growing up, I had friends whose
parents had the rule: Don't be out too late or come home early. In
my house, by contrast, my parent's rule was, of course, depending
on how old we were and other factors, 8 o'clock, 9 o'clock, 10
o'clock. We knew exactly what time we were supposed to be home.
For
my friends, it wasn't quite as clear. Whether they were out too
late sometimes depended on the mood of their parents when they got
home. And there was always the argument: "Isn't 5 a.m. early? You
said to be home early." We didn't have that problem. In our house,
not only was it a set time; it was the kitchen clock. It wasn't my
watch; it wasn't Dad's watch; it wasn't the alarm clock. It was the
kitchen clock, and that was the rule. This provided a certain
certainty.
I
don't mean to make light of these issues. If you violated these
rules, you got grounded. You didn't wind up getting excluded from
the Medicare program. There's also the possibility that your
allowance may have been docked. But you didn't wind up being stuck
with civil penalties that vastly exceeded the total amount ever
paid by the program.
To
protect themselves and patients under these circumstances, doctors
and other providers need to have clear notice of what the rules are
and what the standards in claims processing are going to be. There
needs to be an appeal process regarding exceptions so that, in
individual cases, we can address those issues. There also needs to
be an appeal, an avenue, to challenge arbitrary and capricious
policies at the outset, before the claims are submitted, before the
false claims exposure is incurred.
Timothy Blanchard is a
partner in the Los Angeles law firm of McDermott, Will and Emery.
His practice focuses on health care regulatory issues including
fraud and abuse and the development and implementation of health
care compliance programs, especially Medicare.
CONTROLLING ACCESS TO MEDICAL
TECHNOLOGY
SUSAN BARTLETT FOOTE:
I
want to focus today on the issues of medical technology. There is
extraordinary innovation going on in the medical technology field.
Extraordinary? It is epic.
The
National Research Council just came out with a report,
Networking Health. That report talks about the extraordinary
activities in biochips and implanted chips; continuous monitoring;
sensor technology; microelectron devices. The interface with the
Internet and the information technology is also quite
extraordinary. And this is on top of quite extraordinary advances
in medicine. Many of us, including beneficiaries of the Medicare
program, can look forward to a greatly improved quality and length
of life.
So
it's critically important that these new technologies and advances
to improve our future are integrated into our health care delivery
system, particularly Medicare, which all of us will be part of at
age 65. I don't think the public understands how important that
is.
Today, these innovations, breakthroughs,
and improvements on existing devices bang right up against this
huge Medicare bureaucracy, this bill-paying service. This system
can't move efficiently and effectively to address these kinds of
changes. It's not easy to play the role of prudent purchaser and
evaluator and rational decision-maker, but the Medicare program has
singularly failed in this regard. We have a lot to learn from the
private purchasers. They don't do it perfectly, but I think there
is something to be learned from how the private sector makes these
kinds of decisions.
It's
also important to know, when you're learning about Medicare
coverage, that there are some things that aren't covered. So it
doesn't matter if they're "reasonable" and "necessary" because
they're not part of the program. We're in the middle of a big
debate about whether or not pharmaceuticals should be a covered
service. They're not part of the Medicare program, no matter how
reasonable and necessary a physician might find them to be.
What
is reasonable and necessary? It has been said twice, but there is
no formal definition. It's been internally defined by HCFA, and
that's one of the big problems for innovative medical technology
companies. Uncertainty--as to what you must show HCFA--is in
conflict with innovation.
The
uncertainty has been extreme. For years, manufacturers and
physicians have had to guess at the criteria and often hang on the
words of HCFA officials when they testify in Congress or give
speeches to trade associations to try to figure out the meaning of
"demonstrated effectiveness." What does it mean? It has been
evolving over time, which is frustrating.
Focus on the policy implications. It's
never been part of a national policy debate, but what should the
Medicare program consider? What are the criteria that we think it
should address? In order to determine whether something is covered
or not, there are two paths. The local process is the path for most
technologies. The national process addresses at this point less
than 10 percent of the new technologies.
The
local coverage process has been described at some length, with all
of its problems. But it is a very difficult process to navigate and
leads to significant variation from time to time. Things will be
covered in Northern California and not Southern California. What
standards are applied is not known. In fact, the last study on how
the local coverage process works, I believe, was done in 1984.
There are a lot of questions about how
well this process works, a lot of anecdotes about how poorly it
works, and Timothy Blanchard could go into greater detail on all of
those problems.
The
national coverage process is really in formation. There are a lot
of reasons why a national process makes sense, and a lot of reasons
why the medical technology industry is rather nervous about such a
process, particularly as administered by HCFA. It is true, as you
move to evidence-based medicine, that you would want evidentiary
review. But if it is not a process that people have confidence in,
they might prefer to stick with the local one and get a good
decision in one jurisdiction--maybe not a good one in another, but
not closed out of the system altogether.
There is some justification for a national
process, and for technologies brought into the national process, it
is absolutely essential that the process work. But increasingly,
HCFA has made what they call a "non-coverage" decision. If at the
national level you get a non-coverage decision, that technology or
procedure will not be available to any Medicare patient anywhere,
because the local carriers must follow the national process.
What
is the status of the national coverage process reform? The process
itself and the criteria have been in flux or unknown for a long
time. In 1989, there was a proposed rulemaking; that failed. In
1996, there was an effort to do rulemaking, and that failed.
Behind Closed Doors
There is an opportunity to reform the national process. It
occurred recently because some of the medical device companies
cannot operate well under the existing national process: no rules
clearly articulated, no notice of when the technology was going to
be evaluated, no access to any of the information or data that the
evaluators used. In the recent past, HCFA would gather together
some of their carriers and, behind closed doors, would make crucial
decisions. When rumors of national non-coverage decisions would
leak out, there would be near hysteria because the consequences of
such a decision were so high and the ability to engage in a
discussion on the merits of the technology was simply not
available.
Medical device companies explained this
process to Members of Congress. They were shocked, including
Congressman Bill Thomas, the chairman of the Health Subcommittee of
Ways and Means. He couldn't believe that this is how America's
Medicare program made decisions, behind closed doors, in a black
box, no one knowing who the decision-makers are. He contacted the
General Accounting Office (GAO) and asked them to look at this
process.
The
GAO concluded that the process violated the Federal Advisory
Commission Act, the same act that the Clinton Administration
violated in 1993 by doing their health care reform plan behind
closed doors. This controversy created an opening and an incentive
for officials at HCFA, who said previously that this process was
not a high priority for them. This created a legal obligation to
revise their national coverage process.
Here's the status now of the reform of the
national coverage process. HCFA decided to handle this issue in
three steps. First, they announced a new process. It was not by
rule; it was by a notice. It describes how they would engage in
decision-making in the future.
They
created an advisory committee, modeled on the FDA Advisory
Committees, that would give them help in reviewing national
coverage applications, and they have now begun to set up these
advisory committees. Quite an impressive group of individuals have
volunteered to participate. They're fairly well structured, at
least in terms of who can participate. They've had two meetings of
the executive committee of this advisory committee.
HCFA
also said they were going to propose a true rule, a more formal
process, to develop the criteria that they had failed to do in
1989. We're still waiting for that proposed rule. Just a couple of
weeks ago, they said before they do a proposed rule, they're going
to do an interim "pre-pre" proposal. I think they're concerned
about controversy. They'll lay some stuff out first and see what
they get. But it's uncertain. We're two years into this reform, and
we still have a long way to go.
Cumbersome Process
Think of this process in the context of medical technology and
innovation. We've really paralyzed our national coverage process
while we've been "reforming" it. Decisions are not being made. You
try to fix something that's broken using legislative pressure and a
lobbying effort, yet the "fixing process" is a fairly long and
involved one, and some critical issues are still unresolved. Step
back for a minute and think about it.
-
What are the issues? What are the kinds of
things we should be thinking about if we were going to redesign how
we make Medicare coverage decisions, in light of the incredible
benefit and yet the potential high cost of these new medical
technologies?
-
Who should be deciding? Physicians?
Bureaucrats? Patients?
-
How do we create a decision-making model
so that the best decisions are made?
-
What should be the process? How open
should the process be? Who should be able to participate? Who are
the stakeholders, including the industry, patients, physicians?
This
is a really hard nut to crack. What should be the standards and the
criteria and the methodology that is part of the application? What
should a manufacturer of a new technology, or a new drug, or the
proponent of a new procedure have to show? How much evidence? What
kind of evidence? What kind of standards?
For
example, there are issues unresolved on cost-effectiveness. Should
cost be a criterion that HCFA considers in making coverage policy
decisions? If so, how do they make it? What methodology do they
use? By whose standards or perspectives is cost measured? The
patient? The manufacturer? The hospital? Society?
These are all critically important public
policy issues, yet they are never discussed, and HCFA has been
unable to resolve them.
Lost Time
Timing is also critical, especially with new medical
technologies. If you have processes and bureaucracies that take
one, two, or three years, you're going to be past a medical
innovation's life cycle and miss an opportunity for access to some
of these new medical technologies. So these issues are ones that
we, as a society, Congress and HCFA, have not resolved after 25
years in the program. It's time to look at them.
Once
a coverage decision is made, that's not the end of the story. The
technology or the procedure has to be integrated into the Medicare
program, either in the inpatient diagnostic-related groups (DRGs)
on the hospital side or the outpatient facilities or the
physicians' offices.
Just
recently, some changes really showed me how inadequate the Medicare
bureaucracy is in dealing with new medical technology. Most of the
technologies have been used in the inpatient setting. Major medical
procedures used to put people in the hospital for three weeks or
four weeks. Now advanced procedures can be done in an outpatient
setting or with a short hospital stay. Much better for the patient;
much better for the program; much cheaper.
During debate on the Balanced Budget Act
of 1997, there was discussion of whether or not the Medicare
prospective payment system (PPS) that has been used in hospitals
since 1984 should be carried forward to the outpatient setting,
which continued to be paid on the cost-based reimbursement. Last
spring, HCFA issued a proposed rule that would apply a prospective
payment model to the outpatient system. It is very complicated, if
you think about it: taking all the procedures that are done in the
outpatient setting, thousands of them, and grouping them together
and then creating Medicare payment rates for these groups.
In
reviewing that proposal, it became clear the prices that were set,
and the groupings that were created, were based on data that were
available before 1996. This is to be applied to the year
2000: The base is 1996? There are a whole lot of new and improved
technologies on the market, now available, previously available and
covered in the Medicare program. But suddenly, there was a new
payment system that wasn't going to take any of that new
development into account.
Representatives of the medical device
industry wisely pointed this out to Congress, and in the Balanced
Budget Refinement Act passed last fall, with the help of Senator
Orrin Hatch (R-UT) and Representative Bill Thomas (R-CA), Congress
added new provisions to create transitional rules for new medical
technologies that were on the market after 1996. Congress
provided also some add-on payments for technologies that were newer
and categorized into existing groupings; their prices and costs
weren't calculated into these groupings. This is just a tiny piece
of what will be a 700-page HCFA rule. It will have lots of other
issues as well.
Provisions were passed last year in the
Balanced Budget Refinement Act. Now we are seeing how they might be
implemented, and you can see where frustration with the Medicare
program really boils over. There was a notice published just last
week. The title of it says it all: "Process to Identify and Obtain
Codes for Items Potentially Eligible for Payment as New
Technologies or Transitional Pass-Throughs Under the Outpatient
Perspective Payment System." A mouthful.
HCFA
basically said that if you want your medical technology to be
considered a new technology and your technology is not on their
list, if you want to be considered, you have to apply for a special
code. The process of application is two years, although the
Medicare bureaucracy might be able to issue temporary codes for
payment. But your paperwork all had to be sent in by April 1, 2000.
The coverage decision or the decision about whether or not your new
technology is accepted could be made in July. It could be made in
October. But, of course, if you didn't have a payment code, it
could be 2001 or 2002.
These are medical technologies that are
currently available in the Medicare program in the
outpatient setting. But they are currently not coded in the proper
way, and they fall short of Medicare's bureaucratic requirements.
Here you have a critical problem: If you're going to change the
payment structure, how are you going to integrate new medical
technologies into this changed payment structure? So HCFA tells the
industry, "You have got a long and complicated road ahead."
On
my good days, I think it's just the Medicare bureaucracy and its
complex structure and the thousands of claims they have to process.
On my bad days, I think maybe they really are trying to discourage
the integration of new medical technology into the Medicare
program. I don't like to have to say that, or even think that, but
it just appears to me that this is not a technology-friendly
system. The result is that the uncertainty and the bureaucratic
complications are harming medical innovation, deterring investment
in medical innovations. The reason: The process is so uncertain, so
irrational.
Venture capitalists have said that to me
that the reimbursement uncertainty is so great that no matter how
good the technology looks as a potential health care innovation,
they are afraid to invest. So it's an investment issue. For the
patient and the doctor at the bedside, we may be losing some
incredible benefits in a rich and exciting field. And for
physicians and hospitals, God knows how they have to cope with this
when they know that good things are available and are not
integrated into the Medicare system.
My
view is that we really need to start from scratch. We need to think
about our goals in terms of health care technology, and then we
need to work backwards to design a new system so that there is
access for patients to these technologies in the Medicare
program.
Susan Bartlett Foote is an associate professor
at the University of Minnesota in the Division of Health Services
Research and Policy. Her research is focused on the public policies
of health care services, with particular emphasis on innovation and
medical technology. She is author of Managing the Medical Arms
Race: Innovation and Public Policy in the Medical Device
Industry. She was also a Robert Wood Johnson Health Policy
Fellow and a senior legislative assistant in the office of Senator
David Durenberger of Minnesota.
THE BUREAUCRATIC CONTROL OF DOCTORS
WILLIAM G. PLESTED, M.D.:
As a
cardiovascular surgeon, I spend my life putting my hands onto, or
actually into, real living human beings. So let me share with you
some of the ways that Medicare actually second-guesses, and even
controls, what I do. Some of this, of course, will be repetitive,
but I think that that's very good; it highlights the magnitude of
the problem.
There's a blatant way, of course, that the
Medicare bureaucracy, or HCFA, controls what I do, and that's by
covering or not covering a particular service or operation. As
you've heard, there are national policies. Historically, they have
been developed by a committee of local carrier medical directors.
They got together, without any process or guidelines, or any other
known or published data, to make these national coverage decisions.
This process became a subject of hearings held last year by
Chairman Bill Thomas.
But
remember: As has been pointed out, national coverage decisions
account for only 10 percent of the decisions about what is covered
and what is not, so that even if they get through a huge body of
work, it will only be a 10 percent answer to the problem. Ninety
percent of the policies are made locally by the local carrier
medical directors. Here, we continue with no process
whatsoever.
I've
learned that it's important to look at the way people report, and
to whom they report, and it tells you something about the job they
do. It tells you about who controls the process. Local carrier
medical directors report to the division of program integrity of
HCFA, not to the division of clinical standards and quality. And,
of course, that's why the local carrier medical directors are so
interested in fraud and abuse and in finding out wrongdoing among
physicians. They don't even report to the division of quality and
clinical standards.
But
there is no set protocol for the decisions that they make regarding
Medicare coverage. There is huge variation. A medical director can
have an advisory committee, and some do. They don't need to follow
that advice. Many don't, and it's really absolutely unknown how
they arrive at the coverage decision, whether they discuss it over
the breakfast table at home or whatever. But a coverage decision is
made, and that's the way local coverage decisions are made, and, of
course, this leads to huge regional variation.
One
of the biggest complaints that HCFA has had about physicians in
recent years is that there are regional variations in the treatment
that physicians give patients. There are huge variations, and it
leads to bizarre results. In one Medicare area, there is no
Medicare coverage for lipid profiles in the initial evaluation of a
diabetic. Professionals say this is an absolute must. Who should
make this decision?
What
I do involves the sickest and frailest of our senior citizens with
cardiovascular disease. Consider this: It is forbidden to do a
routine screening evaluation with a physical examination and
pre-operative screening test for these Medicare patients. HCFA does
not allow screening evaluations.
Consider the Medicare patient who may have
underlying heart disease. Not being a specialist in the clinical
evaluation of cardiology, I am not going to do the evaluation as
well. I do it better than most surgeons because I'm a cardiac
surgeon. But in order for me to get that patient covered for a
thorough screening evaluation, I must state that I think the
patient has heart disease. I am then at risk of being
charged with fraud and abuse, saying that I think the
patient has something just so that he can be protected from
something that can be easily found by a pre-operative
evaluation.
Consider the PSA test. This is a screening
test for carcinoma of the prostate. Under current Medicare rules,
it is paid for only if it's positive. Only if you've got
cancer will the Medicare bureaucracy pay. Fortunately, that was
changed just recently. But how? By an act of Congress. It took
congressional intervention to bring some reason to this process at
HCFA. That's just one test for one disease. It took congressional
action.
This
goes on and on. There are bizarre results, and they change from
region to region. It is clear that in one region a problem that a
senior has will not be covered. If he just goes across a state
line, or in some places a county line or just, in some places, up
the street, he's in another Medicare region, and it may be covered.
There is an opportunity for a dot-com business here.
That's the blatant way HCFA tells me what
to do. There are subtle ways. We hear a lot about downcoding and
upcoding, about how physicians feel that they are not being fairly
reimbursed for something that they do, and how they'll charge for
something that's a little higher on the coding scale so that they
get what they consider fair payment for their efforts.
HCFA Downcoding
HCFA actually downcodes blatantly and subtly. They certainly
have a list of the most costly diseases to the program, and they
continually downcode the reimbursement for this. There is no
question that, regardless of how conscientious a physician is, he
can reach a point where he can't tolerate this. He cannot continue
to do what he does at too low a cost.
This
is especially obvious in some very complex surgical procedures.
Again, among the sickest of the patients, the most complex
procedures are costly. The Medicare reimbursement has been reduced
to levels that the most competent, experienced physicians,
surgeons, are telling patients, "You know, I've quit doing this in
my practice." They are referring them to teaching institutions,
where they can have these procedures done by physicians in
training, because they are reimbursed at a different level.
Rigid Pricing
The uniform Medicare reimbursement-by-procedure code is another
unique problem. The federal government has the idea that if you
have a certain procedure, you should be paid uniformly. Some cases
are difficult, and some cases are easy; but in the long run, it
will even out.
There are obvious problems with this. No
other sector of any economy works this way. I can't imagine trying
to tell people that you would pay the same for a week-old loaf of
bread as an hour-old loaf of bread. There are variations. So the
uniform Medicare price makes absolutely no sense.
What
really happens with a uniform price is that practitioners who are
the most talented at, say, a surgical procedure attract the most
difficult cases. Therefore, they uniformly get markedly underpaid
for this, and pretty soon, guess what? They quit doing it, and they
do easier things on less sick patients, because they can do it.
They can do those much better and much faster, and the
reimbursement is better. This process punishes the most skilled
physicians and shifts the sickest and most complex cases to those
who are least able to handle them.
Clearly, price controls don't work.
They've never worked. A basic standard payment schedule is
something that has political appeal, but it will work only if there
is an ability for individual practitioners to set their own
conversion factors and to balance-bill, which is another
subject.
Medicaid also comes under HCFA. Some of
the problems we see in Medicare are even worse in the Medicaid
system. In the last month or so, in California, we just found out
that we now have the honor of being number 50 in the 50 states in
amount of money spent per Medicaid recipient for their medical
care.
Vulnerable Seniors
Consider also the Medicare appeals process for the denial of
claims. For the senior population that I deal with every day,
believe me, they know you can't fight City Hall. It's beyond their
ability.
You've heard of the problems: The process
is way too long. They don't have the energy or the means to carry
it out. And unfortunately, with some of the diseases they have,
they simply are not around by the time the system gets down to the
resolution of their particular problem. The whole process is
complex. They need help, and many of them cannot afford to get the
type of help that they need to fight a denial of claims.
Again, Chairman Bill Thomas introduced a
bill to set some time parameters that will help this situation. It
will also address the problem of Medicare directly based on
Medicare policy. Now you can only appeal an individual denial. You
can't appeal the Medicare policy that led to that individual
denial. And even if you had 100 individual denials, that doesn't
affect the policy that gave rise to those denials. So that would
also be changed in Congressman Thomas's bill.
The
Medicare system today is an exercise in chaos. We're all familiar
with the recent attention that's been given to the IRS and its
thousands of pages of regulations. Since we are a competitive
society, HCFA is clearly the IRS of the new millennium. There are
100,000-plus pages of HCFA regulations involving the Medicare
program.
For
a physician, this simply means that there's no way I can follow all
the rules. I can't know 100,000 pages of rules, and I can't follow
them. I can't follow them when I am asked to see patients faster
and faster and faster, make more complex decisions regarding more
complex technology, and keep track of more than 100,000 pages of
rules and regulations.
So
this is a chaotic system, and we have people making decisions about
the coverage for my patients who are reporting to an officer who is
looking at fraud and abuse. We are criminalizing the practice of
medicine, and that must stop.
The
determination of whether or not someone is covered must be made in
a straightforward public process. It should take into account the
science and the literature. This can be done. It isn't that
difficult. It certainly doesn't take thousands of pages of
regulations. This problem must be fixed with a major overhaul of
the Medicare program.
Dr. William G. Plested
is a member of the board of trustees of the American Medical
Association, and a thoracic and cardiovascular surgeon in private
practice since 1970. He is a graduate of the University of Colorado
and got his M.D. degree from the University of Kansas Medical
School. He pursued his surgical internship and residence at the
UCLA School of Medicine. Dr. Plested is also a former president of
the California Medical Association.